Related Experiment Video
Updated: Sep 8, 2025
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Robert L Hollis1, Alison M Meynert2, Caroline O Michie3
1Nicola Murray Centre for Ovarian Cancer Research, Cancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK.
Summary
High-grade serous ovarian carcinoma (HGSOC) molecular subtypes impact survival and chemotherapy response. Identifying these subtypes, like BRCA2-mutant and CCNE1-gained, aids in tailoring treatments for better patient outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- High-grade serous ovarian carcinoma (HGSOC) is a prevalent cancer type with frequent recurrence and chemoresistance.
- Understanding the interplay of genomic and transcriptomic alterations is crucial for predicting patient outcomes and treatment responses.
- Current knowledge on the relationship between gene sequence, copy number, and expression levels in HGSOC is limited.
Purpose of the Study:
- To conduct a multiomic characterization of a large HGSOC cohort (n=362) with detailed clinical data.
- To investigate the associations between specific molecular events and patient subgroups.
- To define the relationship between gene sequence, copy number, and gene expression in HGSOC.
Main Methods:
- Multiomic profiling (genomic, transcriptomic) of 362 HGSOC cases.
- Detailed clinical annotation and subgroup analysis.
- Statistical analysis of survival data and treatment response rates.
Main Results:
- BRCA2-mutant and EMSY-overexpressing HGSOC cases showed improved survival and chemotherapy response.
- CCNE1-gained cases had shorter survival but similar treatment response rates.
- Homologous recombination repair (HRR) gene aberrations conferred a survival benefit across transcriptomic subtypes.
- RB loss co-occurred with HRR aberrations and was associated with favorable survival in HRR-aberrant cases.
Conclusions:
- Molecular subtyping of HGSOC provides a high-resolution view of the tumor landscape.
- Specific molecular alterations (e.g., BRCA2 mutations, HRR aberrations) identify patient groups likely to benefit from targeted therapies.
- Further research is needed to develop novel treatment strategies for HGSOC patients with unfavorable molecular profiles.
